Peptides for the treatment of oxidative stress related disorders

An isolated peptide, or peptide mimetic thereof, being no longer than 25 amino acids comprising a sequence as set forth in SEQ ID NO:

• 3, wherein the isolated peptide increases viability of a cell under oxidative stress conditions.

An isolated peptide, or peptide mimetic thereof, no longer than 25 amino acids comprising at least 2 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO:

• 1, and a pharmaceutically acceptable carrier, wherein the isolated peptide increases viability of a cell under oxidative stress conditions.

An isolated peptide, or peptide mimetic thereof, no longer than 25 amino acids comprising at least 2 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO:

• 2, wherein the isolated peptide increases viability of a cell under oxidative stress conditions.

A pharmaceutical composition comprising an isolated peptide, or peptide mimetic thereof, no longer than 25 amino acids comprising at least 2 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO:

• 1, and a pharmaceutically acceptable carrier, wherein the isolated peptide increases viability of a cell under oxidative stress conditions.

A pharmaceutical composition comprising an isolated peptide, or peptide mimetic thereof, no longer than 25 amino acids comprising at least 2 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO:

• 2, and a pharmaceutically acceptable carrier, wherein the isolated peptide increases viability of a cell under oxidative stress conditions.

A pharmaceutical composition comprising an isolated peptide or peptide mimetic thereof comprising an amino acid sequence as set forth in SEQ ID NO:

• 24, and a pharmaceutically acceptable carrier.

A method of treating an oxidative stress-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated peptide, or peptide mimetic thereof, no longer than 25 amino acids comprising at least 2 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO:

• 1, and a pharmaceutically acceptable carrier, wherein the isolated peptide increases viability of a cell under oxidative stress conditions, thereby treating the oxidative stress-related disorder.

A method of treating an oxidative stress-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated peptide, or peptide mimetic thereof, no longer than 25 amino acids comprising at least 2 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO:

• 2, and a pharmaceutically acceptable carrier, wherein the isolated peptide increases viability of a cell under oxidative stress conditions, thereby treating the oxidative stress-related disorder.